Tempus AI (NASDAQ:TEM) Trading Down 3% Following Insider Selling

Shares of Tempus AI, Inc. ( NASDAQ:TEM – Get Free Report ) dropped 3% during mid-day trading on Friday following insider selling activity. The stock traded as low as $46.76 and last traded at $47.40. Approximately 3,575,738 shares were traded during trading, a decline of 25% from the average daily volume of 4,750,433 shares. The stock had previously closed at $48.86. Specifically, CEO Eric P. Lefkofsky sold 562,345 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $50.93, for a total value of $28,640,230.85. Following the completion of the sale, the chief executive officer now directly owns 9,457,283 shares in the company, valued at $481,659,423.19. This represents a 5.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website . Also, Director Nadja West sold 809 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $51.11, for a total value of $41,347.99. Following the completion of the sale, the director now owns 37,705 shares of the company’s stock, valued at $1,927,102.55. This trade represents a 2.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here . In other Tempus AI news, COO Ryan Fukushima sold 20,000 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $51.15, for a total value of $1,023,000.00. Following the completion of the sale, the chief operating officer now directly owns 924,460 shares in the company, valued at $47,286,129. This represents a 2.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website . Analyst Upgrades and Downgrades TEM has been the subject of several recent analyst reports. Piper Sandler lowered their price target on Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Morgan Stanley increased their price target on Tempus AI from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday. William Blair restated a “market perform” rating on shares of Tempus AI in a report on Tuesday, February 25th. Wolfe Research downgraded Tempus AI from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Finally, Loop Capital decreased their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Tempus AI presently has a consensus rating of “Moderate Buy” and an average price target of $61.18. Tempus AI Stock Up 0.5 % The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The stock has a fifty day moving average of $54.30 and a 200-day moving average of $52.44. Institutional Inflows and Outflows A number of hedge funds have recently bought and sold shares of TEM. Sigma Planning Corp bought a new position in Tempus AI in the third quarter valued at approximately $1,323,000. GSA Capital Partners LLP bought a new position in Tempus AI in the third quarter valued at approximately $306,000. Sumitomo Mitsui Trust Group Inc. grew its stake in Tempus AI by 1,591.2% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after purchasing an additional 1,145,698 shares in the last quarter. First Horizon Advisors Inc. bought a new position in Tempus AI in the third quarter valued at approximately $30,000. Finally, The Manufacturers Life Insurance Company grew its stake in Tempus AI by 10.2% in the third quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock valued at $1,686,000 after purchasing an additional 2,765 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors. Tempus AI Company Profile ( Get Free Report ) Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Featured Stories Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter .